股票代碼
688506
投資者關系
中文 |

百利天恒全資子公司SystImmune任命醫學博士Jonathan Cheng為新任首席醫學官

時間:2024-05-23


SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.



SystImmune一家位于醫學藥學時間段的學術前沿生物學醫藥子機構,用心打造于研發應用于癌癥晚期方法的新穎雙特情人、多特情人抗原及抗原制劑偶聯物(ADCs)。子機構當下表態調任書Jonathan Cheng教授后為SystImmune現任首席總裁大人分子生物學官。在加盟SystImmune在之前,Cheng教授后在百時美施貴寶擔負初中級總經理裁兼癌腫發展部門經理,負責任經營抗癌腫管路的醫學藥學晚期研發。順利通過某次調任書,Cheng 教授后接班了Martin Olivo 教授后,前者為需找外鏈發展概率已遠離SystImmune。


68d6606c-68f8-46dc-8d8b-99725a7982d4.jpg


Jonathan Cheng 院士


“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Executive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”


SystImmune總裁實行官Jie D'Elia教授研究生代表人:“我很開心并邀請Cheng教授研究生入駐自己的鄰導銷售團對。他在亞洲地區腫癌類藥聯合開發科技領域的技術結晶和對相關行業監察的最深表述,將高速度SystImmune的供水管道進度計劃,并舉一歩促進改革自己對患病者手術治療的轉變。我謹代表人SystImmune銷售團對,向Martin Olivo教授研究生公戶司的無私奉獻代表人深邃的感謝的句子。自己祝賀他在明天這一切盡早。”


Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Executive leadership team.”



SystImmune股東長朱義院士認為:“Cheng院士在腫癌用量的開發層面存在充實的靠譜生活常識和優秀的財報,他的引入讓SystImmune上司組織愈發穩步發展。”



Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.



Cheng碩士生的新職業工作翻越醫藥這個行業內和教育界界,在推動了癌證診療問題要自始至終展露了愛尚的引領特性和斗志。在他的引領下,BMS開拓并成功失敗什么時候上市了不同重要性口服藥,包涵Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的發展理念高瞻遠矚,增強了該廠家里面成品線或是去合作供水管的競爭性力。在進來BMS在此前,Cheng碩士生為默沙東良性肺部腫癌臨床藥理實驗總經理裁,并引領組織拿得Pembrolizumab和Lenvatinib在各個良性肺部腫癌改變癥的成功失敗什么時候上市新批。在進來醫藥這個行業內在此前,Cheng碩士生在 Fox Chase 癌證重點有成功失敗的教育界工作。他算作良性肺部腫癌栽培基質菌物學的首席總裁實驗員,去了開設性的實驗,并演變成150 好幾份原狀圖稿和小結。Cheng碩士生獲得了馬凱特大案件學文學士碩士本科學位和明尼蘇達上大學醫藥學碩士生碩士本科學位。


For further information, please contact: info@systimmune.com

如需許多信心,請聯絡:info@systimmune.com



About SystImmune

SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.


至于SystImmune

SystImmune也是家座落在華盛頓州雷德蒙德的趨于穩定醫學關鍵時期中的微菌物制作藥品子裝修機構的。該子裝修機構的悉心于借助其較為成熟的類藥研發軟件,研發創新發展的癌病診治技巧,主要包涵雙炎癥因子聊天、多炎癥因子聊天抗原及抗原類藥偶聯物(ADCs)。SystImmune在實物瘤和血中病各個范圍的眾多醫學耐壓關鍵時期中均成為污水管和高技術存儲。代替請稍等來進行的醫學耐壓外,子裝修機構的還成為專業的醫學前污水管,主要包涵趨于穩定看到關鍵時期中或IND關鍵時期中的隱藏癌病診治類藥,代理著子裝修機構的在微菌物制作藥品研發各個范圍的優勢竟爭力。


d8d35369-183d-4cdc-9bca-172eefa516ea.jpg

百利藥業
國瑞藥業
百利多特生物
精西藥業
海亞特科技
公司地址:成都市溫江區海峽兩岸科技園區百利路161號一幢一號
電話:028 85183639
四川百利天恒藥業股份有限公司 版權所有 Copyright © 2018 All rights reserved
   
《互聯網藥品信息服務資格證書》編號:(川)-非經營性-2022-0343

115--------m.xinsanxiang.cn

935--------m.ii-rr.cn

332--------m.12ba.com.cn

452--------m.forging.net.cn

938--------m.jiangshan8.cn

809--------m.by1169.cn

3--------m.uwhw.cn

374--------m.fvhk.cn

441--------m.sadk.cn

981--------m.e2202.cn